Pucotenlimab Plus Becotatug Vedotin in Perioperative Treatment of Locally Advanced Resectable Head and Neck Squamous Cell Carcinoma
A phase 2 trial of Pucotenlimab in head and neck squamous cell carcinoma, run by Lepu Biopharma Co., Ltd., now recruiting.
Overview
Pucotenlimab Plus Becotatug Vedotin in Perioperative Treatment of Locally Advanced Resectable Head and Neck Squamous Cell Carcinoma is a phase 2 interventional study registered as NCT07586124 by Lepu Biopharma Co., Ltd., with 80 participants planned, started 2026-07-06 and due to reach its primary completion in 2027-12. Interventions recorded: Becotatug Vedotin for Injection, Placebo, Pucotenlimab Injection. Conditions listed: Head and Neck Squamous Cell Carcinoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialMRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)
Shares Pucotenlimab, Lepu Biopharma.
- TrialA Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcin
Shares Pucotenlimab, Lepu Biopharma.
- TrialA Study to Evaluate MRG003 vs Cetuximab/Methotrexate in in the Treatment of Patients With RM-SCCHN
Shares Lepu Biopharma, Head and neck squamous cell carcinoma.
- TreatmentMRG003
Shares Lepu Biopharma, Head and neck squamous cell carcinoma.